Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease

Biomarkers in Medicine

Volumn 8, Issue 8, 2014, Pages 977-987

  Harutyunyan, Marina ^a   Johansen, Julia S ^b   Mygind, Naja D ^a   Reuter, Simon B ^a   Kastrup, Jens ^a  

^a Mental Health Center Glostrup   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biomarker; coronary artery disease; inflammation; ischemia; YKL 40

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELL PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LONG ACTING DRUG; NITRATE; PROTEIN YKL 40; UNCLASSIFIED DRUG; ADIPOCYTOKINE; BIOLOGICAL MARKER; CHI3L1 PROTEIN, HUMAN; GROWTH PROMOTOR; LECTIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE CONTROL; DISEASE MARKER; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; PROTEIN YKL 40 BLOOD LEVEL; ADVERSE EFFECTS; BLOOD; CASE CONTROL STUDY; COMPLICATION; DISEASE COURSE; FOLLOW UP; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADIPOKINES; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GROWTH SUBSTANCES; HUMANS; LECTINS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84908291033     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.20     Document Type: Article

References (35)

1. Hansson GK. Inflammatory mechanisms in atherosclerosis. J. Thromb. Haemost. 7(Suppl. 1), 328-331 (2009
2. Schultz NA, Johansen JS. YKL-40 - A protein in the field of translational medicine: a role as a biomarker in cancer patients?. Cancer 2(3), 1453-1491 (2010
3. Boot RG, van Achterberg TA, van Aken BE et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler. Thromb. Vasc. Biol. 19(3), 687-694 (1999
4. Francescone RA, Scully S, Faibish M et al. Role of YKL- 40 in the angiogenesis, radioresistance, and progression of glioblastoma. J. Biol. Chem. 286(17), 15332-15343 (2011
5. Kzhyshkowska J, Gratchev A, Goerdt S. Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark. Insights 2, 128-146 (2007
6. Nishikawa KC, Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp. Cell Res. 287(1), 79-87 (2003
7. Brochner CB, Johansen JS, Larsen LA et al. YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers. J. Histochem. Cytochem. 60(3), M188-M204 (2012
8. Lee CG, Da Silva CA, Dela Cruz CS et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu. Rev. Physiol. 73, 479-501 (2011
9. Chupp GL, Lee CG, Jarjour N et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N. Engl. J. Med. 357(20), 2016-2027 (2007
10. Junker N, Johansen JS, Hansen LT et al. Regulation of YKL-40 expression During genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci. 96(3), 183-190 (2005
11. Nielsen AR, Plomgaard P, Krabbe KS et al. IL-6, but not TNF-Alpha, increases plasma YKL-40 in human subjects. Cytokine 55(1), 152-155 (2011
12. Rathcke CN, Kistorp C, Raymond I et al. Plasma YKL-40 levels are elevated in patients with chronic heart failure. Scand. Cardiovasc. J. 44(2), 92-99 (2010
13. Harutyunyan M, Christiansen M, Johansen JS et al. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology 217(6), 652-656 (2012
14. Hedegaard A, Ripa RS, Johansen JS et al. Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand. J. Clin. Lab. Invest. 70(2), 80-86 (2010
15. Wang Y, Ripa RS, Johansen JS et al. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand. Cardiovasc. J. 42(5), 295-302 (2008
16. Kastrup J, Johansen JS, Winkel P et al. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur. Heart J. 30(9), 1066-1072 (2009
17. Harutyunyan M, Gotze JP, Winkel P et al. Serum YKL-40 predicts long-Term mortality in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial. Immunobiology 218(7), 945-51 (2013
18. Mathiasen AB, Harutyunyan MJ, Jorgensen E et al. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. Scand. J. Clin. Lab. Invest. 71(5), 439-447 (2011
19. Kucur M, Isman FK, Karadag B et al. Serum YKL-40 levels in patients with coronary artery disease. Coron. Artery Dis. 18(5), 391-396 (2007
20. Gislason GH, Rasmussen JN, Abildstrom SZ et al. Long-Term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur. Heart J. 27(10), 1153-1158 (2006
21. Ho PM, Spertus JA, Masoudi FA et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch. Intern. Med. 166(17), 1842-1847 (2006
22. Bojesen SE, Johansen JS, Nordestgaard BG. Plasma YKL-40 levels in healthy subjects from the general population. Clin. Chim. Acta 412(9-10), 709-712 (2011
23. Nojgaard C, Host NB, Christensen IJ et al. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron. Artery Dis. 19(4), 257-263 (2008
24. Johansen JS, Lottenburger T, Nielsen HJ et al. Diurnal, weekly, and long-Time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol. Biomarkers Prev. 17(10), 2603-2608 (2008
25. Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?. Immunobiology 217(5), 483-491 (2012
26. Mathiasen AB, Henningsen KM, Harutyunyan MJ et al. YKL-40: a new biomarker in cardiovascular disease?. Biomark. Med. 4(4), 591-600 (2010
27. Kim HM, Lee BW, Song YM et al. Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with Type 2 diabetes mellitus. Cardiovasc. Diabetol. 11(1), 84 (2012
28. Mygind ND, Harutyunyan MJ, Mathiasen AB et al. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflamm. Res. 60(3), 281-287 (2011
29. Lee CG, Dela Cruz CS, Herzog E et al. YKL-40, a chitinase-like protein at the intersection of inflammation and remodeling. Am. J. Respir. Crit. Care Med. 185(7), 692-694 (2012
30. Rathcke CN, Vestergaard H. YKL-40 - An emerging biomarker in cardiovascular disease and diabetes. Cardiovasc. Diabetol. 8, 61 (2009
31. Rathcke CN, Thomsen SB, Linneberg A, Vestergaard H. Variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and prediction of fatal and non-fatal ischemic stroke. PLoS ONE 7(8), e43498 (2012
32. Mygind ND, Iversen K, Køber L et al. The prognostic significance of the inflammatory biomarker YKL-40 in relation to mortality in all-comers. a follow-up study after 11 years. J. Intern. Med. 273(2), 205-216 (2013
33. Rathcke CN, Raymond I, Kistorp C, Hildebrandt P, Faber J, Vestergaard H. Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population. Int. J. Cardiol. 143(1), 35-42 (2010
34. Kjaergaard AD, Bojesen SE, Johansen JS, Nordestgaard BG. Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann. Neurol. 68(5), 672-680 (2010
35. Johansen JS, Bojesen SE, Tybjaerg-Hansen A, Mylin AK, Price PA, Nordestgaard BG. Plasma YKL-40 and total and disease-specific mortality in the general population. Clin. Chem. 56(10), 1580-1591 (2010